---
title: "\"Performance\" LEPU BIO turned a loss into a profit of 261 million RMB for the whole year, achieving profitability in its first year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280439703.md"
description: "LEPU BIO-B announced its full-year results for the year ending last December, with revenue of RMB 935 million, an increase of 154.2% year-on-year. It turned a loss into a profit of RMB 261 million, achieving profitability in its first year, compared to a loss of RMB 411 million in the same period last year; earnings per share were RMB 0.15. No dividend was declared. Under non-International Financial Reporting Standards measurement, LEPU BIO approached breakeven last year, recording an adjusted net loss of approximately RMB 30.6 million"
datetime: "2026-03-25T08:36:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280439703.md)
  - [en](https://longbridge.com/en/news/280439703.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280439703.md)
---

# "Performance" LEPU BIO turned a loss into a profit of 261 million RMB for the whole year, achieving profitability in its first year

LEPU BIO-B (02157.HK) announced its full-year results for the year ended last December, with a revenue of RMB 935 million, an increase of 154.2% year-on-year. It turned a loss into a profit of RMB 261 million, achieving profitability in its first year, compared to a loss of RMB 411 million in the same period last year; earnings per share were RMB 0.15. No dividend was declared.

Under non-International Financial Reporting Standards measurement, LEPU BIO approached breakeven last year, recording an adjusted net loss of approximately RMB 30.6 million

### Related Stocks

- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [02157.HK](https://longbridge.com/en/quote/02157.HK.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)

## Related News & Research

- [FDA approves FoundationOne CDx as TEPMETKO companion diagnostic in NSCLC](https://longbridge.com/en/news/287246470.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)